AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$BHC

Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say

Bausch Health (BHC) reported Q3 earnings, with total Bausch + Lomb revenues at $1.38B, meeting estimates and up 7.3% YoY. Excluding B+L, revenues were $1.57B, beating estimates and up 11.9% YoY. Segments like Salix and Dermatology showed significant growth.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 10:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 2:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BHCNeutralHigh
01

Why it matters

The earnings release provides fresh data that could influence short‑term price action and sector sentiment.

02

Market read

First‑time disclosure of quarterly results; investors will reassess earnings outlook and guidance.

03

What to watch

Potential headwinds from regulatory scrutiny and foreign exchange impacts on international sales.

Relevance 8/10Novelty 8/10Timing: post-market release

Background

Bausch Health (BHC) released its Q3 earnings, detailing segment‑level revenue versus analyst estimates.

Company-level read

Ticker impact

$BHCNeutralHigh confidence
Context

Bausch Health reported Q3 earnings with revenue beating estimates across most segments, providing fresh financial data.

Expected impact

potential modest upside as market prices in revenue beat

Evidence & confidence

First report of the quarter's numbers; revenue beat on key segments may lift the stock, though mixed performance in surgical segment tempers enthusiasm.

Market effects

Sector

Positive revenue surprise may lift the broader health‑care sector, especially pharma and vision‑care peers.

Regional

North American health‑care stocks could see modest gains.

Global

Limited to investors tracking US health‑care earnings; no immediate global macro effect.

Counterpoint

What could challenge this read

The surgical segment missed estimates, suggesting underlying cost pressures that could outweigh the revenue beat.

Key entities

  • company
    Bausch Health Companies Inc.

    US‑listed health‑care company reporting Q3 earnings.

Read at source← All news

StoryBausch Health posts strong Q3 2026 results, raises full‑year outlook and launches $50 M buyback

Also covered by

4 outlets

Related articles

OCT 29
$BHCMedAI 8/10

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call

Bausch Health (BHC) reported Q3 revenue growth in international and Solta Medical segments, with Solta seeing 18% reported growth. The company reduced net debt by $521M in Q3 and announced a $50M share repurchase program. BHC updated its 2026 outlook, expecting 8% revenue growth and 13% adjusted EBITDA growth. Management remains focused on portfolio performance and operational improvements.

finance.yahoo.com2 min
OCT 28
$BHCHighAI 8/10

[Bausch Health Companies Q3 2026 Earnings Call] Bausch Health Raises Guidance Again as Quarterly Adjusted EBITDA Tops $1 Billion for First Time; Warns of $400–$500 Million XIFAXAN Headwind in 2027

Bausch Health (BHC) reported Q3 2026 revenue of $2.94B, up 10% YoY, with adjusted EBITDA surpassing $1B for the first time. The company raised full-year guidance but warned of $400M-$500M XIFAXAN headwind in 2027 due to Medicare rebates. Salix segment grew 16%, driven by XIFAXAN. Net debt reduced by $1B YTD, with plans for debt redemptions and share repurchases.

finance.biggo.com3 min
OCT 28
$BHCHighAI 8/10

Bausch Health Q3FY26 Results: Adjusted EBITDA up 32% to $1.3 billion

Bausch Health reported a 32% YoY increase in adjusted EBITDA to $1.305 billion for Q3FY26, exceeding $1 billion for the first time. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and cash flow, citing strong performance. Net debt was reduced by $521 million during the quarter. Salix segment drove growth with a 16% revenue increase, while Solta Medical saw reported revenue grow 18% but organic revenue decline 4%.

scanx.trade3 min